CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (521)	12/14/1999 10:42:00 AM
From: Mike McFarland	Read Replies (1) of 675

<novel vision-sparing treatments for glaucoma> Cambridge NeuroScience Receives Two U.S. Patents And Three U.S. Patent Allowances biz.yahoo.com The issuance of these US patents will expand the Company's small molecule patent portfolio to more than 45 US patents, with corresponding issued patents or pending patent applications in many countries around the world. The claims covered by these patents provide additional support for Cambridge NeuroScience's collaboration with Allergan in the discovery of novel vision-sparing treatments for glaucoma, and should also benefit the Company's efforts to discover and develop treatments for chronic pain, stroke, traumatic brain injury and Parkinson's disease. All over the map here...maybe that is why there seems not be be much interest in the stock--saying nothing specific. Somebody noted on the BVF thread that Lampert had got rid of his position these past months...would love to know why, it wasn't like he had a ton of money in it.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next